TrialRheumatology international2022

Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.

Maxime Dougados et al.PubMed ↗Publisher ↗

No numbers read from the abstract.